AdvisorShares Investments LLC Invests $1.51 Million in Abivax SA Sponsored ADR $ABVX

AdvisorShares Investments LLC acquired a new stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) in the 4th quarter, Holdings Channel.com reports. The institutional investor acquired 11,200 shares of the company’s stock, valued at approximately $1,510,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in ABVX. Bank of America Corp DE grew its stake in Abivax by 56.1% in the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after purchasing an additional 1,990 shares during the last quarter. Cubist Systematic Strategies LLC lifted its holdings in Abivax by 34.3% in the first quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock valued at $63,000 after acquiring an additional 2,595 shares during the period. Millennium Management LLC raised its stake in shares of Abivax by 6.0% during the 1st quarter. Millennium Management LLC now owns 987,414 shares of the company’s stock worth $6,171,000 after buying an additional 56,235 shares during the period. Woodline Partners LP raised its stake in shares of Abivax by 319.5% during the 1st quarter. Woodline Partners LP now owns 201,924 shares of the company’s stock worth $1,262,000 after buying an additional 153,788 shares during the period. Finally, XTX Topco Ltd acquired a new position in shares of Abivax during the 2nd quarter worth approximately $139,000. 47.91% of the stock is currently owned by institutional investors.

Abivax Trading Up 2.4%

NASDAQ ABVX opened at $132.63 on Friday. The stock has a market cap of $10.57 billion, a PE ratio of -25.46 and a beta of 0.84. Abivax SA Sponsored ADR has a twelve month low of $5.69 and a twelve month high of $148.83. The stock has a fifty day simple moving average of $118.43 and a 200-day simple moving average of $119.92.

Abivax (NASDAQ:ABVX) last posted its earnings results on Friday, May 22nd. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.94) by $0.23. The firm had revenue of $1.56 million for the quarter, compared to analyst estimates of $0.40 million. Research analysts predict that Abivax SA Sponsored ADR will post -3.27 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently weighed in on ABVX. BTIG Research reaffirmed a “buy” rating and set a $150.00 target price on shares of Abivax in a research note on Wednesday, February 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Abivax in a research note on Monday, April 20th. Wedbush initiated coverage on Abivax in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $110.00 price objective for the company. Wall Street Zen raised Abivax from a “sell” rating to a “hold” rating in a research note on Saturday, May 23rd. Finally, Jefferies Financial Group initiated coverage on Abivax in a research note on Monday, March 16th. They issued a “buy” rating and a $160.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Abivax has a consensus rating of “Moderate Buy” and a consensus price target of $137.15.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.